ReviewClinical endoscopy2024
Surveillance for metachronous cancers after endoscopic resection of esophageal squamous cell carcinoma.
Review in Clinical endoscopy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Gel Immersion Endoscopic Mucosal Resection With Submucosal Injection for Superficial Esophageal Squamous Neoplasms (With Video).DEN open · 2027Article
- Nonspecific mediastinal lymphadenopathy is associated with metachronous multiple cancers following endoscopic submucosal dissection of esophageal squamous cell carcinoma.Clinical and experimental medicine · 2026Article
- Recent advancement in size measurement during endoscopy.Clinical endoscopy · 2026Review
- Risk factors for metachronous esophageal squamous cell carcinoma after endoscopic submucosal dissection: a multicenter cohort study integrating overall risk prediction and timing of recurrence.Frontiers in medicine · 2026Article
- Post-endoscopy esophageal squamous cell carcinoma with invasion of the muscularis mucosa or deeper detected in surveillance endoscopy after esophageal endoscopic resection.Esophagus : official journal of the Japan Esophageal Society · 2025Article
- Navigating the Treatment Landscape for Widespread Superficial Esophageal Squamous Cell Neoplasia.Gut and liver · 2025Article
- Feasibility and safety of endoscopic submucosal dissection for superficial cancer of the remnant esophagus after esophagectomy.Esophagus : official journal of the Japan Esophageal Society · 2025Article
- Recent advance in early oral lesion diagnosis: the application of artificial intelligence-assisted endoscopy.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The literature pertaining to surveillance following treatment for esophageal squamous cell carcinoma (SCC) was reviewed and summarized, encompassing the current status and future perspectives. Analysis of the standardized mortality and incidence ratios for these cancers indicates an elevated risk of cancer in the oral cavity, pharynx, larynx, and lungs among patients with esophageal SCC compared to the general population. To enhance the efficacy of surveillance for these metachronous cancers, risk stratification is needed. Various factors, including multiple Lugol-voiding lesions, multiple foci of dilated vascular areas, young age, and high mean corpuscular volume, have been identified as predictors of metachronous SCCs. Current practice involves stratifying the risk of metachronous esophageal and head/neck SCCs based on the presence of multiple Lugol-voiding lesions. Endoscopic surveillance, scheduled 6-12 months post-endoscopic resection, has demonstrated effectiveness, with over 90% of metachronous esophageal SCCs treatable through minimally invasive modalities. Narrow-band imaging emerges as the preferred surveillance method for esophageal and head/neck SCC based on comparative studies of various imaging techniques. Innovative approaches, such as artificial intelligence-assisted detection systems and radiofrequency ablation of high-risk background mucosa, may improve outcomes in patients following endoscopic resection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.